Wishing everyone a safe and relaxing Fourth of July holiday! #IndependenceDay

Happy National Intern Day! Thanks to our summer interns, Denise Nguyen, DJ Johnston, and Sol Feder, for all of their hard work this summer!

Aura’s second quarter 2024 financial results and corporate update are now available. Read the full press release here: bit.ly/3X63Co9

Aura announced Phase 2 end of study data of bel-sar will be presented at The Retina Society Annual Meeting. Aura will host a virtual ocular oncology investor event on 9/12/2024, at 8:00 am ET. To register for the Aura virtual event, click here: bit.ly/3X1xnoH

Join Aura Biosciences $AURA for a virtual ocular oncology investor event on Sep. 12 @ 8am ET with Dr. Ivana Kim, MD & Dr. Prithvi Mruthyunjaya, MD, MHS to discuss the Phase 2 end of study data evaluating bel-sar in early-stage choroidal melanoma. Register: bit.ly/3XoQbQi

This morning, Aura reported positive Phase 2 end of study results evaluating bel-sar as a first-line treatment option for early-stage choroidal melanoma. Read the full release here: bit.ly/3TmwKoL

We are thrilled to welcome Sabine Brookman-May, MD, FEBU, as our SVP, Therapeutic Area Head Urologic Oncology! Sabine D. Brookman-May

Join Aura Biosciences $AURA for a virtual urologic oncology investor event on Thurs. Oct 17 at 4:30pm ET featuring Max Kates, MD, Joe Jacob, MD, MCR, Neal Shore, MD, FACS, and Gary Steinberg, MD, FACS, who will discuss early NMIBC data. Register: bit.ly/4dnqcgD

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 6 oncodaily.com/positive/100-i… This week, we continue featuring 100 influential women in oncology, and here is the list of the next 10 remarkable leaders who are making profound impacts on

We are looking forward to Jill Hopkins, Aura’s CMO and President of R&D, presentation tomorrow at Eyecelerator @ AAO 2024!

Join us today at 4:30pm ET for our virtual urologic oncology investor event! Register here: bit.ly/4dnqcgD

This afternoon, Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer. Read the full release here: bit.ly/4dZ9Efu

Urologic Oncology key opinion leader, Gary Steinberg, MD, was interviewed by Urology Times regarding bel-sar’s mechanism of action. Check out the full article here: urologytimes.com/view/gary-stei…

Aura’s third quarter 2024 financial results and a corporate update are now available. Read the full press release here: bit.ly/3AD2rUB

We are excited to share that an article discussing the treatment of conjunctival melanoma cell lines with bel-sar was published in IOVS, an ARVO Journal. Thanks to Dr. Martine Jager for her partnership on the article. The full article can be found here: bit.ly/3YJVyJk

We are grateful we had the opportunity to participate in the WuXi Global Forum, where Jill Hopkins, Aura’s CMO and President of R&D, discussed our pipeline and our mission to innovate the future of cancer care to cure patients and preserve organ function. lnkd.in/eZDQHh5J

The team came together in celebration of Rare Disease Day 2025. We are on a mission to grow as an innovative global oncology company that positively transforms the lives of patients. Rare Disease Day reminds us of why the work we do matters!

Today, we reported our second quarter 2025 financial results and recent business updates. Read the full announcement: bit.ly/3UrrsbC

Aura’s third quarter 2025 financial results and corporate update are now available. Read the full press release here: bit.ly/4hXWPpb

Aura Biosciences is proud to celebrate Rare Disease Day 2026! This year, our team came together to support patients and families living with rare diseases, including rare cancers like early #choroidalmelanoma, through a simple but meaningful action. Many employees across the